These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
418 related articles for article (PubMed ID: 6222288)
1. A case for concern? Gartland A Nurs Times; 1983 May 4-10; 79(18):10-1. PubMed ID: 6222288 [TBL] [Abstract][Full Text] [Related]
2. Depo-Provera: just another contraceptive? Jones M Fertil Contracept; 1978 Apr; 2(2):26-9. PubMed ID: 12336094 [TBL] [Abstract][Full Text] [Related]
3. Depo Provera: still controversial. Wren LM Int Health News; 1988 Feb; 9(2):2-3, 8. PubMed ID: 12179873 [TBL] [Abstract][Full Text] [Related]
4. The use of Depo-Provera in East London. Savage W Fertil Contracept; 1978 Jul; 2(3):41-7. PubMed ID: 12260723 [TBL] [Abstract][Full Text] [Related]
5. Drug regulation in the United States and the United Kingdom: the Depo-Provera story. Richard BW; Lasagna L Ann Intern Med; 1987 Jun; 106(6):886-91. PubMed ID: 2953290 [TBL] [Abstract][Full Text] [Related]
6. The Food and Drug Administration and medroxyprogesterone acetate. What are the issues? Rosenfield A; Maine D; Rochat R; Shelton J; Hatcher RA JAMA; 1983 Jun; 249(21):2922-8. PubMed ID: 6221125 [TBL] [Abstract][Full Text] [Related]
7. Depo Provera: a profile of current users. Jarman H; Kovacs GT; Westcott M Aust N Z J Obstet Gynaecol; 1990 Feb; 30(1):74-6. PubMed ID: 2140675 [TBL] [Abstract][Full Text] [Related]
8. Depo-Provera: a critical analysis. Minkin S Women Health; 1980; 5(2):49-69. PubMed ID: 6451987 [TBL] [Abstract][Full Text] [Related]
9. Metabolic parameter, bleeding, and weight changes in U.S. women using progestin only contraceptives. Mainwaring R; Hales HA; Stevenson K; Hatasaka HH; Poulson AM; Jones KP; Peterson CM Contraception; 1995 Mar; 51(3):149-53. PubMed ID: 7621683 [TBL] [Abstract][Full Text] [Related]
10. Extracts from the report on the Joint IGCC/IFRP East and South East Asia Seminar on Regional Fertility Research. Mcdaniel EB IGCC News; 1980 Jan; 5(3):1-4. PubMed ID: 12179403 [TBL] [Abstract][Full Text] [Related]
11. Depo-Provera--ethical issues in its testing and distribution. Potts M; Paxman JM J Med Ethics; 1984 Mar; 10(1):9-20. PubMed ID: 6231379 [TBL] [Abstract][Full Text] [Related]
12. Depo Provera. Position paper on clinical use, effectiveness and side effects. Bigrigg A; Evans M; Gbolade B; Newton J; Pollard L; Szarewski A; Thomas C; Walling M Br J Fam Plann; 1999 Jul; 25(2):69-76. PubMed ID: 10454658 [TBL] [Abstract][Full Text] [Related]
14. The Depo-Provera public hearing. Dening FC Midwives Chron; 1983 Jul; 96(1146):246. PubMed ID: 6225940 [No Abstract] [Full Text] [Related]
15. Medroxyprogesterone acetate [Depo Provera] injections. Development of striae. Gupta M Br J Fam Plann; 2000 Apr; 26(2):104-5. PubMed ID: 10773604 [TBL] [Abstract][Full Text] [Related]
16. Long-term depot medroxyprogesterone acetate (Depo-Provera) use in inner-city adolescents. Polaneczky M; Liblanc M J Adolesc Health; 1998 Aug; 23(2):81-8. PubMed ID: 9714170 [TBL] [Abstract][Full Text] [Related]
17. A randomized, single blind comparative trial of norethindrone enanthate and depo-medroxyprogesterone acetate in Bangladesh. Swenson I; Khan AR; Jahan FA Contraception; 1980 Mar; 21(3):207-15. PubMed ID: 6446442 [TBL] [Abstract][Full Text] [Related]
18. FDA gives final approval to Depo amid concerns over safety, cost and coercion. Wash Memo Alan Guttmacher Inst; 1992 Nov; (17):2-3. PubMed ID: 12344620 [TBL] [Abstract][Full Text] [Related]
19. Testing times for women in body lab. Bacon W Lamp; 1983 May; 40(3):38-40. PubMed ID: 6228701 [TBL] [Abstract][Full Text] [Related]